Gilead's Oncology and Inflammation Wave: Why the Market is Underpricing Diversification

Related Articles

Is Gilead's GH31 Acquisition a Game-Changer for Its Oncology Pipeline

8 months ago

Intuitive Machines: Why the Market is Underpricing the Moon's Infrastructure Play

4 months ago

Antonio Filosa's Stellantis: Why the Market Is Underpricing the Turnaround

4 months ago

Why Did Gilead Pay $7.8 Billion for Arcellx

8 months ago

Category

You may also like

Stock News•1 week ago

CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy

CG Oncology is positioned to enter the NMIBC market with cretostimogene, supported by randomized Phase 3 data and a clean tolerability profile. Its $1B+ cash funds operations through 2029, and imminen...

CGON

Share

News•1 months ago

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios...

Share

Stock News•3 months ago

Gilead: Buy The Distortion Before Q2 Clears It Up

Gilead Sciences' fundamentals remain intact despite a temporary $11.5B IPR&D charge that distorts optics. Its HIV franchise is growing 8% with patent protection through 2036, while an oncology inflect...

GILD

Share